Standard BioTools, is engaged in product rationalization, cost-cutting and operational efficiency measures in an attempt to turn its business around and transition to profitability. The company’s ...

Standard BioTools Inc (NASDAQ:LAB) is set to release its Q2 2025 earnings on August 11, 2025. The consensus estimate for Q2 2025 revenue is $39.82 million, and the earnings are expected to come in at ...

Standard BioTools Inc. will release its first quarter 2025 financial results on May 6, 2025, after market close, and will host a conference call and webcast at 4:30 p.m. ET that same day to discuss ...

Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling ...

Standard BioTools reports preliminary 2024 revenue of $174 million and will present at the J.P. Morgan Healthcare Conference. Standard BioTools Inc. announced preliminary, unaudited revenue results ...

Every investor in Standard BioTools Inc. (NASDAQ:LAB) should be aware of the most powerful shareholder groups. With 38% stake, institutions possess the maximum shares in the company. That is, the ...

Standard BioTools expects the restructuring costs to be paid over the next several months. The company indicated that the operational changes are intended to support the execution of its long-term ...

In other recent news, Standard BioTools Inc. reported a revenue beat in its first earnings report following the divestiture of SomaLogic, though it missed bottom-line expectations. The company has set ...